Coeptis Therapeutics Holdings, Inc. announced on June 26, 2025, the filing of a registration statement on Form S-4 with the Securities and Exchange Commission (SEC). This filing is related to the company's previously announced definitive merger agreement with Z Squared Inc. The Form S-4 includes a preliminary proxy statement/prospectus regarding the proposed transaction.
The registration statement has not yet become effective, and the information contained within it is subject to change. This filing is a necessary regulatory step in the process of completing the merger. It provides important information about Coeptis, Z Squared, the merger agreement, the business combination, and the planned spin-out of Coeptis' biopharmaceutical operations.
Coeptis urges its investors, stockholders, and other interested persons to read the preliminary proxy statement/information statement/prospectus, as well as other documents filed with the SEC. This regulatory action indicates progress towards the anticipated closing of the transaction in the third quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.